TWO EMAIL Responses from Innate Immunotherapeutics:
******************************************************************************
Andrew Cooke <Andrew@innateimmuno.com>
Dear ******** ************
Innate Immunotherapeutics Limited trades on the Australian Stock Exchange (ASX) where the code is IIL. Pursuant to ASX listing rules the Company operates under a continuous disclosure regime and accordingly I can confirm that the market is currently fully informed.
We understand that IIL may trade on the over the counter (OTC) market in the US however this is not a formal arrangement endorsed by the Company or which the Company has requested or actually participates in. IIL is not formally listed on any US stock exchange.
Our Register of Members is maintained by Computershare Limited. The Register of Members records all of the holders of the issued capital of the Company including nominee holders. The Register of Members does not record any details in relation to INNMF shares. We understand that many of the nominee holders on our Register of Members may hold shares for or on behalf of persons who have acquired INNMF shares in the US on the OTC, however the Company has no direct or indirect participation in this process.
The current issued capital of the Company is 225,625,991 ordinary fully paid shares, all of which trade on the ASX.
The Company does not offer or sponsor the trading in ADR’s.
Please do not hesitate to contact me if you require any further information.
Kind Regards
Andrew J. Cooke
Company Secretary
Innate Immunotherapeutics Limited
Tel: + 61 (0) 412 090 826
**************************************************************************************
Irene Vanderlaan (Irene@innateimmuno.com>
As mentioned in the announcement, and by Simon on the subsequent Investor Call, the Company is now undertaking a more detailed analysis of individual patients to see if there was in fact a subgroup of patients who did have a favourable response. Until such time as this further analysis is completed and the Company provides a further update to the market, we are unfortunately not able to brief individual shareholders.
Kind regards
Irene Vanderlaan
